Cipla Ltd
CIPLACipla Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: Domestic institutions moved +9.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is building a base (3 weeks in) while the P/E sits at the 64th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −39.2% year on year, and 98% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Cipla Ltd trades at ₹1,419, building a base and 3 weeks into that stage. That is +1.1% against its own 200-day average. It sits at 58% of a 52-week range of ₹1,192 to ₹1,584. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (3 weeks and counting).
Today the stock is building a base — week 3 of stage 1, confirmed. At ₹1,419 it trades +1.1% versus its 200-day average and sits at 58% of its 52-week range (₹1,192–₹1,584).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +165% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (3 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 64th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Cipla Ltd trades at 31.8× P/E, mid-range by its own standards (64th percentile). Its long-run median P/E is 29.7×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 31.8× is mid-range by its own standards (64th percentile), against a long-run median of 29.7× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −26.4% against a −4.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +7.7%/yr price move, ~+8.3%/yr came from earnings growth and ~−0.6 pp from the multiple (roughly flat); over 10y, of the +10.6%/yr price move, ~+13.0%/yr came from earnings growth and ~−2.4 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Cipla Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −37.7% latest against +48.1% at its 12-quarter best), ROCE slipping at 15.7%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +2.2% | +7.4% | +8.0% | +7.4% |
| Profit | −26.7% | +10.9% | +10.1% | +10.8% |
| EPS | −26.4% | +11.4% | +10.0% | +11.0% |
| Share price | −4.3% | +11.2% | +7.7% | +10.6% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
35.8/100 — rank 39 of 43 in Pharma - Formulators · 100% evidence confidence
Cipla Ltd scores 35.8 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 39. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 5.6 + 13.7 + 12.1 + 4.4 = 35.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Cipla Ltd reported ₹7,119 Cr of revenue in the Jun 26 quarter, +2.3% year on year. Over 10 years it has compounded at 7.4% a year. The last full year, FY26, came in at ₹28,163 Cr. The last four reported quarters add to ₹28,323 Cr.
Cipla Ltd reported ₹7,119 Cr of revenue in the Jun 26 quarter, +2.3% year on year. Over 10 years it has compounded at 7.4% a year. The last full year, FY26, came in at ₹28,163 Cr. The last four reported quarters add to ₹28,323 Cr.
FY26 revenue came in at ₹28,163 Cr (+2.2% on the year), capping 10 years at 7.4% compound. The latest quarter (Jun 26) printed ₹7,119 Cr, +2.3% year on year.
Pace check: the last four quarters averaged +1.8% growth against the decade's 7.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +1.8% over the last 4 quarters against +4.1%/yr over the last 8 — stabilising; TTM profit −37.7% vs −12.0%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 17.0% this quarter (−9.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Cipla Ltd's operating margin is 17.0% in the Jun 26 quarter, −9.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0% to 26.0%. The current quarter sits inside that band.
Cipla Ltd's operating margin is 17.0% in the Jun 26 quarter, −9.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0% to 26.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 17.0%, −9.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 17.0%–26.0%.
🚨 Why the margin moved: operating margin went −8.8 pp year on year while gross margin went −6.3 pp — the loss came mostly from the gross line: input costs and pricing.
→ Margins slipped — did that reach the bottom line? Next: profit −39.2% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Cipla Ltd earned ₹786 Cr of net profit in the Jun 26 quarter, −39.2% year on year. Full-year FY26 profit was ₹3,862 Cr. The 10-year compound rate is 10.8%. That is 11.0% of the quarter's revenue. The same quarter a year earlier earned ₹1,292 Cr.
Cipla Ltd earned ₹786 Cr of net profit in the Jun 26 quarter, −39.2% year on year. Full-year FY26 profit was ₹3,862 Cr. The 10-year compound rate is 10.8%. That is 11.0% of the quarter's revenue. The same quarter a year earlier earned ₹1,292 Cr.
Jun 26 profit was ₹786 Cr, −39.2% year on year. On the full year, FY26 printed ₹3,862 Cr (−26.7%), and the 10-year compound rate is 10.8%.
🚨 Why profit moved: revenue contributed +2.3% and the margin −9.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −37.0% vs revenue +1.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 98% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 98% of Cipla Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹3,940 Cr of operating cash against ₹3,862 Cr of profit. After ₹4,115 Cr of capital spending, ₹−175 Cr was left as free cash.
FY26: operating cash of ₹3,940 Cr against reported profit of ₹3,862 Cr, leaving free cash of ₹−175 Cr after ₹4,115 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 98% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 98%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.
Router verdict: the bigger cash user is investment — capital spending ran 2.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹7,592 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Cipla Ltd's cash conversion cycle runs 202 days in FY26, up from 195 days in FY21. Capital spending ran ₹7,592 Cr over the last 3 years. At FY26 sales of ₹28,163 Cr each day of that cycle holds about ₹77.2 Cr, so roughly ₹15,586 Cr sits inside the business at any moment.
FY26: debtors at 73 days, inventory at 252 days — roughly 8.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 202 days, looser than FY21's 195.
The full loop: cash goes out to suppliers and production on day 0; stock waits 252 days to sell; customers pay about 73 days after that; and suppliers themselves are paid at 123 days — netting out to the 202-day cycle.
In money terms: at FY26 sales of ₹28,163 Cr, each day of the cycle holds about ₹77.2 Cr — so the 202-day loop keeps roughly ₹15,586 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹7,592 Cr over the last 3 fiscal years against ₹3,369 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2,042 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 15% and the ROIC − WACC spread is +0.4 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Cipla Ltd earns a ROCE of 15% in FY26. That is up from a trough of 7% in FY17. Return on invested capital clears the cost of that capital by +0.4 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.7% net margin on 0.67× asset turns.
FY26 ROCE is 15%, recovered from a FY17 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.7% net margin × 0.67× asset turns × 1.23× balance-sheet leverage ≈ 11.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 12.4% − 12.0% = a +0.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.02.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Cipla Ltd carries total debt of ₹614 Cr against shareholder equity of ₹34,520 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.05 in FY22 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹614 Cr against shareholder equity of ₹34,520 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.05 (FY22) to 0.02 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 9.7 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 9.7 points of Cipla Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 34.4% of the company. Foreign institutions moved −7.6 points over the same window, to 20.2%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +9.7 points over 8 quarters to 34.4%; Foreign institutions: −7.6 points over 8 quarters to 20.2%; Promoters: −1.7 points over 8 quarters to 29.2%.
Why the register moved: rotation — foreign institutions −7.6 points against domestic institutions +9.7 points over 8 quarters, with promoters −1.7 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Cipla Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Cipla Ltd this page | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Kwality Pharmaceuticals Ltd | 36.6× | ₹2,483 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Cipla Ltd's share price today?
Cipla Ltd trades at ₹1,419, −4.3% over the past year. The company is valued at ₹1,13,955 Cr. The stock sits at 58% of its 52-week range of ₹1,192–₹1,584, +1.1% versus its 200-day average. On the tape, the price is building a base, 3 weeks in. — as of 24 July 2026.
What were Cipla Ltd's latest quarterly results?
Cipla Ltd reported revenue of ₹7,119 Cr and net profit of ₹786 Cr for the Jun 26 quarter. Revenue rose 2.3% and profit fell 39.2% year on year. Earnings per share were ₹9.77. The operating margin was 17.0%, 9.0 pp lower than a year earlier. — as of 24 July 2026.
What is Cipla Ltd's revenue?
Cipla Ltd reported revenue of ₹7,119 Cr in the Jun 26 quarter, +2.3% year on year. For the full FY26 fiscal year, revenue was ₹28,163 Cr (+2.2%). Over the last 10 years revenue compounded at 7.4% a year. — as of 24 July 2026.
What is Cipla Ltd's profit?
Cipla Ltd earned ₹786 Cr of net profit in the Jun 26 quarter, −39.2% year on year. Full-year FY26 profit was ₹3,862 Cr. The operating margin ran 17.0% in the latest quarter. — as of 24 July 2026.
What is Cipla Ltd's market cap?
Cipla Ltd's market capitalisation is ₹1,13,955 Cr at a share price of ₹1,419. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Cipla Ltd's P/E ratio?
Cipla Ltd trades at a P/E of 31.8×, at the 64th percentile of its own 10-year range, against a long-run median of 29.7×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Cipla Ltd pay a dividend?
Yes — Cipla Ltd's dividend payout was 27% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Cipla Ltd overvalued?
On its own history, Cipla Ltd looks mid-range against its own history: its P/E of 31.8× sits at the 64th percentile of its 10-year range (long-run median 29.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Cipla Ltd growing?
Not right now — Cipla Ltd's latest numbers are shrinking: latest-quarter revenue +2.3% year on year, profit −39.2%, and the margin −9.0 pp at 17.0%. The 10-year compound rates are 7.4% (revenue) and 10.8% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Cipla Ltd performing?
Cipla Ltd is building a base, 3 weeks in. Its latest quarter's revenue rose 2.3% and profit fell 39.2% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 3 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Cipla Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −37.7% latest against +48.1% at its 12-quarter best), ROCE slipping at 15.7%. The read comes from the last 12 quarters of growth (revenue growth +1.8% latest, profit growth −37.7% latest, eps growth −37.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Cipla Ltd in an uptrend?
No — the price is building a base (week 3 of stage 1), trading +1.1% versus its 200-day average and at 58% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Cipla Ltd beating the market?
Not lately — on a trailing-13-week view Cipla Ltd is currently behind the NIFTY 500 (3 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +165% against the NIFTY 500's +274% — behind the index over the full window. — as of 24 July 2026.
Will Cipla Ltd's share price go up?
This page publishes no price forecast for Cipla Ltd. What it measures instead: the share price is ₹1,419, the price is building a base 3 weeks in. Its P/E of 31.8× sits at the 64th percentile of its own 10-year range. Direction is not something this site claims to know. — as of 24 July 2026.
Who owns Cipla Ltd?
Promoters hold 29.2% of Cipla Ltd, foreign institutions 20.2%, domestic institutions 34.4% and the public 15.9% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 9.7 points over 8 quarters. — as of 24 July 2026.
Does Cipla Ltd have too much debt?
No — Cipla Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹614 Cr against equity of ₹34,432 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Cipla Ltd's capex?
Cipla Ltd spent ₹7,592 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹4,115 Cr, with ₹2,042 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Cipla Ltd's cash flow?
Cipla Ltd generated ₹3,940 Cr of operating cash flow in FY26 and ₹−175 Cr of free cash flow after ₹4,115 Cr of capital spending. Reported profit that year was ₹3,862 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Cipla Ltd's profit real cash?
Yes — over the last 3 fiscal years, 98% of Cipla Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹3,940 Cr against reported profit of ₹3,862 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Cipla Ltd in its business cycle?
Cipla Ltd's FY26 operating margin was 21.0%, against a 13-year band of 17.0%–26.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 17.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Cipla Ltd story?
The sharpest disagreement: Domestic institutions moved +9.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Cipla Ltd a stock worth studying right now?
This is not investment advice. The machine read: Cipla Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.